This result is concordant with previous studies in gastric cancer, suggesting that cancer-associated promoters overlap with regions targeted by PRC2 epigenetic regulator complex and are particularly sensitive to EZH2 inhibition [3,55]. The gene discussed is EZH2; the disease is gastric cancer.